New syringe design tested for safety in common eye conditions
NCT ID NCT05112861
First seen Apr 25, 2026 · Last updated Apr 30, 2026 · Updated 1 time
Summary
This study tests whether a pre-filled syringe is as safe as the traditional vial for delivering an eye injection (bevacizumab) to treat wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. About 120 participants will receive the injection either from a vial or a pre-filled syringe and be monitored for side effects over 3 months. The goal is to see if the pre-filled syringe is a safe and convenient alternative.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
Springfield, Illinois, 62704, United States
-
Clinical Site
Hagerstown, Maryland, 21740, United States
-
Clinical Site
Chambersburg, Pennsylvania, 17201, United States
Conditions
Explore the condition pages connected to this study.